livemint.com
75%
343
CureVac's covid-19 vaccine triggers immune response in Phase I trial
COVID-19 vaccine triggered an immune response in humans, it said on Monday, putting the German biotech company on track to start mass testing this year as the race to end the pandemic heats up."We are very encouraged by the interim Phase I data," Chief Executive Officer Franz-Werner Haas said in a statement,The biotech firm is using the so-called messenger RNA (mRNA) approach, the same as Moderna as well as BioNTech and its partner Pfizer, although they started mass testing on humans in late July.CureVac said its potential vaccine, known as CVnCoV, was generally well tolerated and results strongly supported the company's plans to launch the final stage of testing on humans before the end of the year.CureVac - backed by German biotech